TITLE

Foetal Allogeneic Intracerebroventricular Neural Stem Cell Transplantation in People with Secondary Progressive Multiple Sclerosis: A phase I dose-escalation clinical trial

AUTHORS

Leone MA[1*], Gelati M[1*], Profico DC[1], Conti C[2], Spera C[2], Muzi G[2], Grespi V[1], Bicchi I[1], Ricciolini C[1], Ferrari D[4], Zarrelli M[1], Amoruso L[1], Placentino G[1], Crociani P[1], Apollo F[1], Di Viesti P[1], Fogli D[1], Popolizio T[1], Colosimo C[2], Frondizi D[2], Stipa G[2], Tinella E[2], Ciampini A[2], Sabatini S[2], Paci F[2], Silveri G[1], Gobbi C[3,6], Pravatà E[3,6,7], Zecca E[3,6], Balzano RF[7], Kuhle J[5], Copetti M[1], Fontana A[1], Carella M[1], D'Aloisio G[1], Abate L[1], Pluchino S[8], Peruzzotti-Jametti L[8] and Vescovi AL[1,4]

* The two Authors contributed equally to the manuscript

1. IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013 San Giovanni Rotondo, Foggia, Italy

2. AOSP Santa Maria, via Tristano di Joannuccio 1, 05100, Terni, Italy

3. Multiple Sclerosis Centre (MSC), Department of Neurology, Neurocentre of Southern Switzerland, EOC, 6900 Lugano, Switzerland

4. BTBS Università Bicocca, piazza della Scienza 2, 20126, Milan, Italy

5. Department of Neurology, University Hospital Basel, and University of Basel/Switzerland

23 6. Faculty of biomedical Sciences, Università della Svizzera Italiana (USI), 6900 Lugano,
24 Switzerland
25 7. Department of Neuroradiology, Neurocentre of Southern Switzerland, EOC, 6900 Lugano,
26 Switzerland
27 8. Department of Clinical Neurosciences and NIHR Biomedical Research Centre, University of
28 Cambridge, CB2 0QQ Cambridge, United Kingdom.
29
30 Corresponding Author: Prof. Angelo Luigi Vescovi. Email vescovia@gmail.com
31 IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013 San Giovanni Rotondo,
32 Foggia, ItalyTel +39 0882 416566
33
34 **ABSTRACT**
35 **Background:** Advanced cell therapeutics are emerging as potentially effective treatments
36 for chronic neurological diseases, including secondary progressive multiple sclerosis (SPMS).
37 Here we report the results of a phase I trial in which good manufacturing practice-grade
38 foetal allogeneic human neural stem cells (hNSCs) were implanted via
39 intracerebroventricular (ICV) injection in 15 individuals with active and non-active SPMS.
40 **Methods:** This is a phase I, open-label, multicentre, dose-escalation, international study. The
41 primary objective was to assess the feasibility, safety, and tolerability of ICV injections of
42 allogeneic hNSCs in patients affected by SPMS over a study follow up of 12 months. We also
43 evaluated the number and type of adverse events (AEs) leading to a maximum tolerated
44 dose, the general health status, and mortality. The secondary objectives were the
45 therapeutic benefit of allogeneic hNSCs using assessment scales, magnetic resonance
46 imaging (MRI), and laboratory and neurophysiologic parameters.

Findings: Fifteen unrelated SPMS patients were enrolled and treated between 2018 and 2020. The participants had a median age of 49.8 years. Their mean extended disability status scale (EDSS) at enrolment was 7.6, the mean disease duration was 22 years, and mean time from diagnosis to progression was 10.1 years. Neither treatment-related deaths nor serious AEs were reported during the study (1 year follow up after treatment). All the other AEs were classified as non-serious and were associated to non-study concomitant therapy or other medical conditions not connected to the experimental treatment. During the study, none of the participants worsened in the progression of their SPMS as shown by the evaluation scales implemented to assess their progress. Laboratory and neurophysiologic parameters showed no clinically significant variations. MRI follow-up showed non-clinically significant type 1, 2, and 3 changes.

Interpretation: The intracerebroventricular injection of foetal allogeneic hNSCs in people with SPMS is feasible, tolerated and safe. Study participants displayed a substantial clinical stability during the 12-month follow-up. The absence of relevant adverse reactions (Ars) arising from the transplantation of hNSCs indicates a short-term neutral balance between benefits and risks and suggests a concrete, though perspective therapeutic possibility for SPMS patients. Further studies are needed to confirm and extend the findings herein and evaluate the actual therapeutic potential of advanced cell therapeutics for a condition where the lack of effective disease modifying therapies is a major unmet clinical need.

INTRODUCTION

Multiple sclerosis (MS) is the most common cause of non-traumatic disability in young adults, with over 2·5 million sufferers worldwide.[1] The last decade has seen a fast development of effective disease modifying treatments (DMTs) for patients with a relapsing remitting form of MS (RRMS).

71 However, as the disease evolves into secondary progressive MS (SPMS), DMTs have limited efficacy.
72 Thus, SPMS patients currently have a major unmet need.[2,3] A solution to the current lack of effective
73 treatments for SPMS may come from emerging cell therapy approaches, which have shown
74 promising initial results in other central nervous system (CNS) diseases, such as amyotrophic lateral
75 sclerosis (ALS) and Parkinson's disease.[4]
76 *In vivo* studies in rodent and non-human primate models of MS have shown that human neural stem
77 cells (hNSCs)[5-8] are an effective and safe tool to induce CNS functional recovery due to their tissue
78 specificity and multiple mechanisms of action.[9,10] hNSCs not only repair the damaged CNS by
79 replacing cells lost to injury, but also exert immunomodulatory actions on both innate and adaptive
80 immune responses via secretion of trophic factors, cross-correction of missing enzymatic activities,
81 and metabolic reprogramming.[11-14] Additional data suggest that delivering these cells directly to the
82 CNS via a single intracerebroventricular (ICV) injection allows maximising the number of cells that
83 reach the CNS[15-17] and may be key to target the intense compartmentalised inflammation that drives
84 progression in SPMS.[18] Indeed, following ICV injection, transplanted hNSCs spread throughout the
85 ventricular and subarachnoid space,[16,19] enabling their inflammation-guided migration into the CNS,
86 where they may reach axons and myelinating cells directly without crossing the blood brain barrier.[20]
87 The ICV cell injection is based on a widely used, technically simple, rapid, and standardised
88 neurosurgical procedure with a minimal rate of complications (6·8%), mainly due to catheter
89 malposition, haemorrhage, and infection (Morgenstern et al., 2016) . ICV is also a relatively
90 standardised experimental procedure, since it has already been used for the injection of growth
91 factors in ALS patients[21] and for chemotherapeutic agents in anti-tumour therapy. [22]
92 Here, we report the results of the first phase I, open-label, multicentre, dose-escalation study in
93 which good manufacturing practice (GMP)-grade foetal allogeneic human neural stem cells (hNSCs)
94 were implanted via intracerebroventricular (ICV) injection in 15 individuals with SPMS. To the best of
95 our knowledge, this is also the largest phase I trial with hNSCs in people with SPMS conducted to
96 date.

97

98 **METHODS**

99 **Study design**

100 In this phase I, open-label, multicentre, international, dose-escalation study, the participating
101 patients were affected by SPMS with progressive accumulation of disability after an initial relapsing
102 course, with or without disease activity. Fifteen patients, between 18 and 60 years of age were
103 enrolled according to a "standard" dose-escalation phase I design following a modified Fibonacci
104 sequence (100%, 60% and 50% dose increments). After the initial screening, all screened patients
105 entered a 3-month run-in phase. After that, the patients were prospectively enrolled into four
106 cohorts receiving four different doses of allogenic hNSCs (5, 10, 16 and 24 million cells).

107 This study was performed in three participating centres located in Italy and Switzerland. The Italian
108 centres, the "IRCCS Casa Sollievo della Sofferenza" Research Hospital (Site 1) and the "Santa Maria di
109 Terni" Hospital (Site 2), recruited the patients. The MSC of the Neurocentre of Southern Switzerland
110 performed the magnetic resonance imaging (MRI) analysis, while ICV treatment was performed at
111 Site 2.

112 The study was approved by the Ethical Committee of the Istituto Tumori "Giovanni Paolo II" (Bari)
113 from the "Fondazione IRCCS Casa Sollievo della Sofferenza" Research Hospital (01PU/2016–21-01-
114 2016); the Ethical Committee of the "Aziende Sanitarie dell'Umbria" (2404/17); the Agenzia Italiana
115 del Farmaco (AIFA); the Istituto Superiore di Sanità (3090(16)-PRE21-1408–06-04-2016). The trial
116 was subsequently registered in the European Clinical Trials Database (EudraCT, 2015-004855-37),
117 and in ClinicalTrials.gov (NCT03282760).

118

119 **Participants**

120 Eligible patients were adults of either sex with a diagnosis of SPMS, with or without disease activity
121 (Lublin 2014) with an Expanded Disability Status Score (EDSS)[23] ≥ 6.5 and ≤ 8, showing a progressive

122 accumulation of disability after initial relapsing course over the 2 years before recruitment (≥ 1.0
123 point for patients with EDSS =6.5 at the time of inclusion, and ≥ 0.5 points for patients with EDSS >
124 6.5 at the time of inclusion), and ineligibility to other therapeutic alternatives (as assessed by the
125 treating neurologist). All patients signed a written informed consent to be enrolled in the study.
126 Exclusion criteria included: other neurologic conditions; psychiatric/personality disorders or severe
127 cognitive decline; history of significant systemic, infectious, oncologic, or metabolic disorders; other
128 autoimmune diseases; chronic infections (HBV, HCV, HIV, tuberculosis); inability to undergo MRI
129 scans; inability to provide informed consent, received immunomodulant/immunosuppressive
130 treatments <6 months before inclusion; participated in other research; any contra-indication to
131 lumbar puncture; and were pregnant or breast feeding.
132 At the end of the run-in period, and if no serious co-morbidity nor health status changes occurred,
133 patients were deemed eligible for the intervention. After eligibility assessment and provision of
134 informed consent, each eligible patient was registered in the "Database for Clinical Studies with
135 Gene and Somatic Therapy" of the "Istituto Superiore di Sanità" (ISS). Before registration, the ISS
136 verified patient eligibility to ensure criteria were respected. Upon registration, the database
137 assigned a unique identification number to each patient which was used for anonymisation
138 purposes.
139 To establish baseline clinical features, a 3-month run-in period was started after the screening
140 examination. All patients were evaluated at the onset and the end of the run-in period by
141 investigating and performing physical and neurological examination, vital signs, pregnancy test in
142 fertile women, haematological and urine tests, lumbar puncture for standard CSF examination and
143 JC Virus test, serum and CSF collection (stored at minus 80 degrees), motor, sensory and visual
144 evoked potentials, optical coherence tomography (OCT), EDSS, MFSC, RAO brief repeatable battery,
145 MS-QOL54 for the evaluation of quality of life (Solari et al. 1999), brain and spinal MRI. At the end of
146 the run-in period, and if no serious co-morbidity nor health status changes occurred, patients were
147 deemed eligible for the intervention. Around 50% of patients had at least one new or one enlarging

148 T2-visibile lesion, while 43% of patients had at least one lesion with contrast enhancement during
149 the run-in period.
150
151
152 **Study objectives and outcomes**
153 The primary objective of the study was to assess the feasibility, safety, and tolerability of foetal
154 allogeneic hNSCs delivered via ICV injection in people with active and non-active SPMS patients by
155 evaluating the following outcomes: mortality, the number and type of adverse reactions (ARs) or
156 events (AEs) leading to a maximum tolerated dose.
157 The secondary objectives were to evaluate the functional effects of hNSC therapetics by monitoring
158 the following outcomes of disease progression: functional disability via EDSS and Multiple Sclerosis
159 Functional Composite (MSFC)[24] ; annualised relapse rate and time to confirmed relapse; cognitive
160 function by Rao's brief repeatable battery [BRB] of neuropsychological tests; visual, sensory and
161 motor functions via combination of electrophysiological measurements (visual, somato-sensory,
162 motor evoked potentials [EP]); and optical coherence tomography (OCT). Brain MRI evaluations
163 were performed to monitor structural changes related to both the intervention and disease activity.
164 MRIs were acquired at the two recruiting centres, using a Philips Ingenia scanner (Philips Medical
165 Systems, Best, The Netherlands) and a Siemens Verio scanner (Siemens, Erlangen, Germany).
166 Sequences type and parameters were harmonised between the two vendors to improve
167 reproducibility. The MRIs were performed at run-in onset (month -3), run-in end (month 0), and at
168 months +1, +2, +3, +4, +5, +6, +9 and +12.
169 Potential effects of the treatment on biomarkers of neuronal loss and inflammation was also
170 evaluated. Cerebrospinal fluid (CSF) and serum neurofilament (NfL) levels were used as markers of
171 neurodegeneration/neuronal damage, while CHI3L1 (also known as YKL-40) as indicator of reactive
172 astrocytes.[25] We also investigated serum and CSF levels of IL-17a, IL-2, IL-8, TNF-α, CCL2, CCL3,

173 CX3CL1, VEGF-a, OPN and GFAP as additional exploratory objectives. All the biomarkers were
174 evaluated in both CSF and serum collected before and after treatment (see table 1 for time points)
175
176 **Clinical evaluation**
177 After ICV injection, the participants were followed up for 12 months post-treatment (**Table 1**).
178 General health status and mortality evaluations were based on the occurrence of any serious co-
179 morbidities or changes in the general health of the participants post-intervention and the number of
180 deaths due to the treatment, or the procedure itself.
181

182

183 Table 1: Clinical trial study plan

	Screening	Run in START	Run in END	Surgery	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12
Informed consent signature	x	x														
Medical history	x															
Neurological history	x															
Physical examination	x	x	x													
Infectious screening	x															
Vital Signs	x	x	x		x		x			x			x			x
Pregnancy test for fertile women	x	x	x													
Hematological tests	x	x	x		x	x	x	x	x	x	x	x	x	x	x	x
Electrocardiogram	x															
Chest X-ray	x															
standard urine test	x	x	x		x		x			x			x			x
Neurological examination	x	x	x		x	x	x	x	x	x	x	x	x	x	x	x
VAS		x	x		x	x	x	x	x	x	x	x	x	x	x	x
EDSS		x	x		x		x			x			x			x
MSFC		x	x		x		x			x			x			x
Evoked potential test		x	x		x		x			x			x			x
OCT		x	x		x		x			x			x			x
Brain and spinal MRI		x	x	x	x	x	x	x	x	x			x			x
RAO battery		x	x		x		x			x			x			x
MS-QOL54		x	x		x		x			x			x			x
Conselling with psycologist	x				x											
Serum collection for biomarkers		x	x		x		x			x			x			x
CSF collection for biomarkers		x	x		x					x						x
JC virus examination		x	x		x					x						x
AE record				x		x	x	x	x	x	x	x	x	x	x	x
Thin slice cranial CT or MRI				x	x											

184

185

186 All AEs were recorded and evaluated for their relationship with the hNSCs or injection procedure.

187 Each AE was classified and categorised according to the International Conference on Harmonisation

188 guidance for Clinical Safety Data Management's Definitions and Standards for Expedited Reporting

189 E2A and the Common Terminology Criteria for Adverse Events (CTCAE). Clinical relapses were

190 defined as the appearance of a new neurologic deficit, or worsening of previously stable or
191 improving pre-existing neurologic deficit, separated by at least 30 days from the onset of a preceding
192 clinical demyelinating event.[26] The neurologic deficit must have been present for at least 24 hours
193 and occurred in the absence of fever (<37 ·5°C) or known infection.
194
195 **hNSCs dosage and production**
196 hNSCs were produced following a previously described method[27] and in full compliance with the
197 conditions and practices required by GMP regulations. The hNSCs consisted of a highly enriched
198 population of cells extracted from a single female foetal human donor (spontaneous miscarriage
199 16weeks after conception) under Ethics Committee approval, with the donors' parents' informed
200 consent, and according to the Helsinki declaration. hNSCs were cultured for 10-17 passages *in*
201 *vitro*.[27], the last passage was performed 24-96 hours before formulation of the final drug product.
202 On the day of treatment, hNSCs were collected from culture flasks, centrifuged counted and
203 suspended in HBSS at a concentration of 50,000 cells/µl. After batch release, the cells were
204 maintained at 4 +/-2 °C for up to 1·5 hours prior to implantation. See Profico et al 2022 for complete
205 quality control strategy for batch release.
206
207
208 **Intervention**
209 Trial participants were admitted to the Neurosurgery Unit of the "Azienda Ospedaliera Santa Maria"
210 (Terni, Italy) for the ICV injection of hNSCs. Before the intervention, they underwent thin-slice cranial
211 CT or MRI scans to evaluate the ventricular system and plan the procedure. Image guidance was
212 provided by the frameless stereotactic AxiEM system (Stealth station AxiEM electromagnetic
213 tracking system, Medtronic navigation, Louisville, CO, USA) to perform the ventricular cannulation.
214 The correct placement of the catheter was verified based on the egress of CSF. Then, a Rickham
215 reservoir was connected to the ventricular catheter. The participants were then prospectively

216 assigned to receive 5 (n=3), 10 (n=3), 16 (n=3), and 24 (n=6) x 10^6 cells ICV. All the participants
217 underwent a post-operative CT scan within 24 hours to evaluate any complications.
218 All the participants received methylprednisolone orally 125 mg 2 hours pre-intervention, and
219 cefazolin 1g IV immediately before and after the hNSCs injection. The immunosuppressive treatment
220 also included oral prednisone with a 28-day taper (consisting of a dose change per week, from 60,
221 40, 20, to 10 mg q.d). The participants also received Tacrolimus (0·05 mg/kg, oral, b.i.d.), 12 hours
222 after the intervention and then every 12 hours, for 6 months. This drug was titrated to maintain
223 blood levels ranging 5–10 ng/ml.
224
225 **Data management and study monitoring**
226 All trial demographic and clinical data was collected by designated investigators at the screening,
227 run-in, and follow-up visits using ad-hoc case report forms (CRFs). A clinical trial monitor periodically
228 reviewed the CRFs with source data verification and requested corrections as needed. The data were
229 then entered into a eCRF and underwent systematic quality control of the study manager prior to
230 database locking. The database was periodically reviewed by an independent Data and Safety
231 Monitoring Board (DSMB) to ensure protocol adherence and to monitor possible AEs. The DSMB
232 made recommendations concerning the continuation, modification, or termination of the trial as
233 needed.
234
235 **Statistical Methods**
236 Demographic, clinical, and laboratory patients' characteristics were reported as median and
237 interquartile ranges (IQR) or as mean and standard deviation (SD), as appropriate, for continuous
238 variables and as frequency and percentage for categorical variables. Normal distribution was
239 checked using the Shapiro-Wilk test. Safety analyses were performed in all subjects receiving at least
240 one injection of hNSCs. All AEs and severe AEs (SAEs) were recorded at follow-up visits and at the
241 end of the study. Exploratory efficacy analyses were conducted fashion in all subjects receiving at

242 least one injection of hNSCs (here, FAS and ITT populations matched). Because of small sample size
243 and of almost all variables having non-normal distributions, pre-post differences (12-month visit vs
244 run-in end visit) were assessed via linear models using ranks. New or enlarging T2-visible lesions and
245 lesions with contrast enhancement were analysed using negative binomial models with follow-up
246 time as the offset and results reported as annualised rates.
247 A p-value <0.05 was considered statistically significant. All analyses have been performed using SAS
248 Release 9.4, SAS Institute, Cary, NC, USA.

RESULTS

Clinical Results

A total of 220 candidates applied to participate in this study between September 26, 2017, and January 13, 2020. After undergoing the screening visit and completing the run-in period, fifteen SPMS patients were enrolled in the study. The participants had a median age of 49.8 years (range: 37.8–56.6), eight of them were females and seven were males (1.14 : 1 ratio), and an almost equal proportion was recruited at the two study sites. The mean EDSS was 7.6 (range 7–8), mean disease duration was 22 years (range 16–29), and mean time from diagnosis to progression was 10.1 years (range: 1–20). All the patients' detailed demographic and clinical characteristics are reported in **Table 2**.

261 Table 2: Demographic data and group assignment.

DOSE	Gender	EDSS	AGE AT TREATMENT (range)
$5*10^6$	M	7,5	55-59
	M	7	50-54
	M	8	50-54
$10*10^6$	M	7,5	36-39
	F	7	50-54
	F	8	50-54
$16*10^6$	F	7	50-54
	F	8	50-54
	F	8	45-49
$24*10^6$	F	7,5	50-54
	F	8	45-49
	M	7	40-45
	F	7	55-59
	M	8	36-39
	F	8	50-54

262 No deaths nor serious ARs were reported during the study period. The AEs that occurred, including
263 their severity, relationship to study and non-study therapies, actions taken, and outcomes are
264 reported in **Table 3**.

265

266 Table 3: Adverse events

Patient	Description of event	expected?	Severity	Relationship to study therapy	Action taken	If other, please specify	New treatment/therapy given/taken?	Outcome (at the end of the study)
#1	Tremor	Yes	Mild	Unrelated	Tacrolimus dose changed		No	Recovered
	Flu like syndrome	No	Mild	Unrelated	None		Yes	Recovered
	Respiratory failure	Yes	Mild	Unrelated	Concomitant therapy changed		Yes	Recovered
	Cataract (left eye; surgical procedure)	No	Mild	Unrelated	None		No	Recovered
	Upper respiratory infection	No	Mild	Unrelated	Concomitant therapy changed		Yes	Recovered
#2	Hyperglycemia	Yes	Moderate	Unrelated	Concomitant therapy changed		No	Recovered
	Urinary retention	Yes	Moderate	Unrelated	Other, specify	Catheterization	Yes	Recovering (improving)
	Back pain	No	Mild	Unrelated	Other, specify	New therapy given	Yes	Recovered
#4	Seizure	Yes	Mild	Possible	Other, specify	Diazepam, levetiracetam	Yes	Recovered
#7	Psychosis	No	Moderate	Unrelated	Concomitant therapy changed		Yes	Recovered
#8	Fracture (right femur)	No	Moderate	Unrelated	Other, specify	Follow-up 10 omitted	No	Recovered with sequelae
#9	Leukoencephalopathy	No	Mild	Unrelated	Other, specify	MRI evaluations	No	Recovering (improving)
	Urinary tract infection	No	Mild	Unrelated	Other, specify	Drugs administration	Yes	Recovered
#12	Depression	No	Moderate	Unrelated	None		No	Unknown
#14	Urinary tract infection	No	Mild	Unrelated	Other, specify	Antibiotics administration	Yes	Not recovered

267 Among these, SAEs (defined as AEs requiring hospitalisation) occurred in 2 patients (2/15), but none
268 of them were related to the hNSC injection: of these two, one patient developed a steroid-induced
269 acute psychiatric disorder 1 month post-injection, but recovered completely within 1 month with the

270 administration of valproate, lorazepam, olanzapine, and psychotherapy; Another patient
271 experienced femur fracture during a physiotherapy session at 18 months post-injection.
272 Other AEs were classified as non-serious and only one was possibly related to the study. This was a
273 patient (1/15) who experienced a first-ever partial motor seizure at month 6 (expected, possibly
274 related to MS). As per the possible complications related to the long-term immunosuppressive
275 treatment, one patient (1/15) developed a tremor during treatment with Tacrolimus which
276 disappeared with dose-adjustment, one patient (1/15) developed respiratory failure, and infections
277 were detected in three patients (3/15) (1 upper respiratory tract, 2 urinary tract). All the other
278 reported AEs were related to non-study concomitant therapy or other medical conditions not
279 related to the experimental protocol. The immunosuppressive treatment was successfully
280 completed by patients. Tacrolimus was well tolerated by all patients except for the one already
281 mentioned. In all patients, Tacrolimus blood levels were within the therapeutic target range (below
282 20 ng/mL).
283 As per the secondary objectives of the study, no changes were measured in EDSS and MSFC for the
284 whole length of the study (**Table 4**).

285

Table 4. EDSS and MSFC evaluation

hNSC Dose		Run-in Phase Onset (N=15)	Run-in Phase End (N=15)	1 month (N=15)	3 months (N=15)	6 months (N=15)	9 months (N=15)	12 months (N=15)	p value
5 millions	MSFC (Total Score)								0.753
	Median	-5.5	-5.5	-5.6	-5.4	-5.6	-5.6	-5.3	
	Nobs	3	3	3	3	3	3	3	
	EDSS								0.114
	Median	7.5	7.5	7.5	7.5	7.5	7.5	7.0	
	Nobs	3	3	3	3	3	3	3	
10 millions	MSFC (Total Score)								0.150
	Median	-6.2	-6.0	-6.0	-6.0	-5.9	-5.9	-5.9	
	Nobs	3	3	3	3	3	3	3	
	EDSS								1.000
	Median	7.5	7.5	7.5	7.5	7.5	7.5	7.5	
	Nobs	3	3	3	3	3	3	3	
16 millions	MSFC (Total Score)								0.924
	Median	-6.0	-5.7	-6.2	-6.1	-5.8	-5.8	-5.6	
	Nobs	3	3	3	3	3	3	2	
	EDSS								1.000
	Median	8.0	8.0	8.0	8.0	8.0	8.0	8.0	
	Nobs	3	3	3	3	3	3	3	
24 millions	MSFC (Total Score)								0.772
	Median	-6.1	-6.1	-6.0	-6.2	-5.9	-6.1	-6.2	
	Nobs	6	6	6	5	3	4	4	
	EDSS								0.831
	Median	7.8	7.8	7.8	7.8	7.8	7.8	7.8	
	Nobs	6	6	6	6	6	6	6	

EDSS: Expanded Disability Status Scale; MSFC: Multiple Sclerosis Functional Composite; Std.dev: Standard Deviation; IQR: Interquartile Range (i.e. first, third quartiles)

Test for linear trend from Run-In End to the end of the study: p-values from linear mixed-effects models

322 The median EDSS score did not change from the end of the run-in phase to the end of the study. Two
323 patients (2/15) had a change in the functional systems score of >1 point, both in the pyramidal area:
324 one decreased from 4.5 to 3.0 and another one increased from 0.0 to 2.0. The MSFC scores also did
325 not significantly change from the end of the run-in phase to the end of the study.
326 None of the patients reported symptoms indicative of clinically active disease and cognitive
327 functions, as measured by Rao's BRB, did not show significant changes during the study period for
328 any test. Neurophysiological parameters were monitored with EPs. Linear model analyses on ranks
329 did not show any variation trends throughout the study for any visual, somatosensory, and motor
330 EPs. We did not observe any changes on the OCT, except for one patient that showed an increase in
331 retinal nerve fibre layer's (RNFL) thickness in both eyes at month 6, which was interpreted as an
332 artefact.
333 As part of the secondary objectives, of the 40 scheduled MRIs for the 15 patients, 25 were
334 completed according to the study protocol and 15 were not performed (11 due to patient refusal,
335 two due to patient inability, two due to the COVID-19 pandemic). One patient did not have a
336 baseline MRI and post-Gadolinium images were not available for 8 MRIs due to exam interruption.
337 Brain changes on MRI were classified as type 1, 2, and 3 to facilitate comparison between time
338 points.
339 Type 1 changes were likely related to the surgical procedure. They included a linear T2-
340 hyperintensity in the parenchyma beneath the surgical right frontal cranial hole, passing through the
341 right frontal lobe white matter to the homolateral ventricle and corpus callosum (**Figure 1**).x

342

Figure 1. Example of type 1 change, interpreted as parenchymal gliotic modifications following ventricular cannulation. Coronal-oblique 3D-T2-FLAIR subtraction map in A (Month 12 minus Run-in End) detected a linearly-shaped positive signal change, passing through the right frontal lobe to the homolateral ventricle. This change corresponded to a subtle contrast-enhancing tract which occurred at Month 1 (B, post-Gadolinium T1-weighted image) at the level of the surgical cranial hole (circle in B). Month 6 (C) and Month 12 (D) T2-FLAIR images demonstrated the persisting chronic changes (arrows).



This was variable across all participants, ranging from a very subtle to a manifest signal change, and it was detectable in all patients on Month 1 images, together with a linear contrast enhancement on the corresponding post-Gadolinium T1-weighted images in most of cases.

Type 2 changes were MS-related and were used to compare the pre-transplantation with the post-transplantation period.

Type 3 changes were undetermined and detected in only one participant, where subtraction images highlighted a triangle-shaped, subtle T2-hyperintense signal change in the left frontal lobe white matter, without contrast enhancement or water diffusion restriction (**Figure 2**).

Figure 2– Type 3 changes. Coronal-oblique 3D-T2-FLAIR subtraction map (Month 6 minus Run-in-End) detects a triangle-shaped, positive signal change in the left frontal white matter (arrows). This corresponded to a subtle T2-FLAIR signal hyperintensity on the corresponding Month 6 source image (B, arrows). No contrast enhancement and/or water diffusivity restriction was noted (not shown).



This change remained stable at the subsequent follow-ups and was categorised as non-specific. This patient had additional MRI follow-up during which the lesion did not change.

Pre-transplantation (during the three-month run-in period), nine new-onset and two enlarging T2-visibile lesions were detected in 7/14 patients (50% of patients, with an average of 1.3 and 0.3 of new and enlarging T2 lesions per patient) (**Table 5**).

372 Table 5 Summary of pre- and post-transplantation new-onset and enlarging T2-visible lesions
373 obtained by using subtraction imaging (see main text for details). N/A = data not available *When
374 the Month12 time-point data was not available, the last previous available data was employed for
375 subtraction

376

	Pre-Transplantation			***Post-Transplantation***		
Subject #	**Compared Time Points**	**Number of New (Enlarging) T2-visibile lesions**	**Monthly Lesion Activity Rate**	**Compared Time Points***	**Number of New (Enlarging) T2-visibile lesions**	**Monthly Lesion Activity Rate**
#1	Run In End – Run In Onset	0	0.00	Month12 – Run In End	8	0.67
#2		0	0.00	Month12 - Run In End	1	0.08
#3		0	0.00	Month12 - Run In End	0	0.00
#4		2	0.67	Month12 - Run In End	6	0.50
#5		1	0.33	Month12 - Run In End	0	0.00
#6		0	0.00	Month12 - Run In End	1	0.08
#7		0	0.00	Month12 - Run In End	0	0.00
#8		0	0.00	Month 6 - Run In End	0 (1)	0.17
#9		0 (2)	0.67	Month12 - Run In End	8	0.67
#10		3	1	Month12 - Run In End	26	2.17
#11		1	0.33	Month12 - Run In End	3	0.25
#12		1	0.33	Month 3 - Run In End	0	0.00
#13		0	0.00	Month 9 - Run In End	0	0.00
#14		N/A	N/A	Month12 - Run In End	6	0.50
#15		1	0.33	Month12 - Run In End	5 (2)	0.58
Total		**9 (2)**			**64 (3)**	

377

378 After transplantation (during the 12-month follow-up period), 64 new-onset and three enlarging T2-
379 visible lesions were detected in 10 out of 15 patients (66% of patients, with an average of 6.4 and 0.3
380 of new and enlarging T2 lesions per patient). The annualised pre-transplantation rate of new or
381 enlarging T2-visibile lesions was 3.30 (95% CI: 1·86–5·83), which was not statistically different (p-

382 value= 0·26) to the post-transplantation rate (4·72, 95% CI: 2·32–9·61). When the 12-month data

383 was not available, the last previously available data was used to compare).

384 Pre-transplantation, 10 lesions with contrast enhancement were detected in 6/14 patients (43%)

385 (**Table 6**).

Subject #	Number of lesions with contrast enhancement (Time point)	Number of lesions with contrast enhancement (Time point)
#1	0	1 (Month6)
#2	0	0
#3	0	0
#4	2 (Run in Onset)	3 (Month3), 2 (Month6)
#5	1 (Run in End)	0
#6	0	0
#7	0	0
#8	0	1 (Month3)
#9	0	1 (Month6)
#10	1 (Run in Onset), 1 (Run in End)	9 (Month3), 12 (Month 6), 4 (Month12)
#11	1 (Run in End)	1 (Month9)

386

387 Table 6 Summary of pre- and post-transplantation lesions showing contrast enhancement on T1-

388 weighted images, detected upon visual inspection. N/A = data not available.

#12	1 (Run in Onset), 1 (Run in End)	0
#13	0	0
#14	N/A	1 (Month12), 1(Month6)
#15	1 (Run in Onset), 1 (Run in End)	4 (Month3)
Total	**5 (Run in End), 5 (Run in Onset)**	**40**

After transplantation, 40 gadolinium enhancing lesions were detected in multiple scans from 8 out of 15 patients. The annualised pre-transplantation rate of lesions with contrast enhancement was 2·86 (95% CI: 1·51–5·40) and it was not statistically different (p-value=0·98) to the post-transplantation values (2·83, 95% CI: 0·92–8·73).

Of note, 40% of the new-onset T2 lesions and the majority of gadolinium enhancing lesions happened in one single patient who had the highest disease activity in the run-in period. Additionally, one patient who showed one new T2 lesion and two lesions with contrast enhancement in the pre-transplantation period, had no new T2 or gadolinium enhancing lesions at follow-up.

Among the laboratory exams performed during the study, the only clinically significant variation was in the number of white blood cells that ranged from a mean of 7·4 x10^9/L at the end of the run-in period to a mean of 8·3 x10^9/L at the 12-month follow-up. The vital signs of the participants (blood pressure and temperature) were within the normal range and urine tests did not show clinically significant abnormalities. Biomarker analyses of NfL and CHI3L1/YKL-40 showed a statistically significant increase in the NfL concentration (pg/mL) at 1 month after intervention in both serum and CSF, followed by a gradual return to pre-intervention values (**Table 7**).

407 Table 7 Estimated marginal means, along with 95% confidence interval, from repeated measurements ANOVA models of serum neurofilament light
408 concentrations (pg/mL) collected in NSC-SPMS patients at different groups and time points. P-values are referred to within-group and within-time
409 comparisons and were derived from statistical contrasts defined into each model

Biomarker	hNSC assigned dose groups	Run-In onset (RSTART)	Run-In end (REND)	1 month (T1)	3 months (T3)	6 months (T6)	9 months (T9)	12 months (T12)	Within-group comparisons (p-values)						
									RSTART vs. REND	T1 vs. REND	T3 vs. REND	T6 vs. REND	T9 vs. REND	T12 vs. REND	p-value for trend
NfL CRMs	5 millions	13.84 (7.85-24.39)	11.33 (6.43-19.97)	31.61 (17.94-55.70)	29.87 (16.95-52.63)	20.62 (11.70-36.33)	12.93 (7.34-22.78)	13.21 (7.50-23.28)	0.552	0.003	0.005	0.079	0.695	0.648	0.664
	10 millions	14.59 (8.28-25.71)	16.91 (9.60-29.80)	45.64 (25.90-80.43)	21.78 (12.36-38.38)	18.21 (10.33-32.08)	17.17 (9.74-30.26)	19.68 (11.17-34.68)	0.660	0.004	0.452	0.826	0.964	0.652	0.825
	16 millions	11.80 (6.70-20.79)	12.33 (7.00-21.73)	98.03 (50.35-190.86)	27.94 (15.85-49.23)	23.07 (13.09-40.65)	14.33 (8.13-25.25)	14.84 (7.62-28.90)	0.896	<0.001	0.018	0.066	0.654	0.626	0.491
	24 millions	18.70 (12.53-27.91)	14.90 (9.98-22.24)	41.41 (27.74-61.81)	26.05 (16.91-40.12)	19.49 (11.41-33.29)	16.18 (8.51-30.79)	14.32 (8.91-23.00)	0.340	<0.001	0.030	0.370	0.814	0.882	0.540
	Overall	14.53 (11.15-18.94)	13.70 (10.51-17.86)	49.19 (37.21-65.03)	26.23 (20.06-34.29)	20.27 (15.33-26.80)	15.06 (11.23-20.20)	15.33 (11.52-20.41)	0.708	<0.001	<0.001	0.019	0.576	0.499	0.078
	Within-time comparisons (p-values)	0.594	0.743	0.090	0.881	0.948	0.905	0.778							
GFAP	5 millions	77.40 (45.16-132.65)	64.20 (37.46-110.02)	79.41 (46.33-136.08)	96.66 (56.40-165.65)	83.13 (48.51-142.47)	71.45 (41.69-122.45)	81.26 (47.41-139.26)	0.259	0.200	0.016	0.121	0.516	0.156	0.846
	10 millions	169.04 (98.64-289.70)	144.04 (84.05-246.85)	184.13 (107.44-315.55)	144.11 (84.09-246.97)	173.45 (101.21-297.26)	191.89 (111.97-328.85)	187.90 (109.64-322.01)	0.333	0.140	0.998	0.262	0.086	0.111	0.469
	16 millions	148.40 (86.59-254.32)	179.56 (104.77-307.73)	222.80 (126.50-392.41)	204.55 (119.35-350.55)	176.34 (102.89-302.20)	197.01 (114.96-337.64)	180.73 (102.61-318.32)	0.250	0.252	0.430	0.912	0.574	0.972	0.957
	24 millions	92.62 (63.28-135.57)	97.47 (66.60-142.67)	110.93 (75.79-162.36)	124.85 (84.58-184.30)	117.19 (77.00-178.37)	110.82 (70.20-174.92)	112.42 (75.25-167.96)	0.661	0.269	0.049	0.215	0.461	0.287	0.301
	Overall	115.80 (90.01-148.99)	112.79 (87.67-145.11)	137.87 (106.77-178.04)	137.34 (106.66-176.83)	131.39 (101.73-169.68)	131.53 (101.45-170.54)	132.72 (102.57-171.71)	0.732	0.015	0.014	0.061	0.070	0.051	0.056
	Within-time comparisons (p-values)	0.155	0.077	0.063	0.303	0.200	0.051	0.131							

410 The same pattern was evident across the four dose groups. These changes are likely due to post-procedure tissue damage that was detectable in all the
411 participants on MRI imaging. On the contrary, GFAP concentration did not show any peculiar pattern and remained stable throughout the trial for all the
412 dose groups (Table 7).

413 **DISCUSSION**

414 The ICV injection of hNSCs was safe and did not lead to clinically relevant AEs post-intervention. The
415 only SAEs that occurred were not related to hNSCs or the intervention, and no withdrawals or
416 deaths were registered. Importantly, none of the patients has shown either a clinical relapse or a
417 progression of their condition during the study period. The follow-up disability evaluation scales and
418 cognitive testing documented clinical stability of all the participants. The neurophysiologic
419 parameters and OCT also showed no significant variations. The MRI disease activity, assessed by
420 annualised rate of new or enlarging T2-visible lesions and lesions with contrast enhancement, was
421 not affected by the treatment. Finally, despite an initial fluctuation of the levels of NfL and
422 CHI3L1/YKL-40, these markers later returned to their baseline values.

423 Currently, there is a lack of treatment options for SPMS. Although another study using a similar NSC
424 preparation and method of administration is underway in another Italian centre (NCT03269071), to
425 our knowledge this manuscript represents the first report of the use of hNSCs in SPMS patients. In
426 addition, this study utilises a cell line that has been already shown safe in a prior clinical trial on ALS
427 (Mazzini et al., 2015, 2019).

428 This study has limitations inherent to its early phase, non-randomised design, and small sample.
429 Also, the fact that some MRIs could not be performed could have weakened the imaging results.
430 Nevertheless, this research provides novel information on the safety and potential effectiveness of
431 this treatment modality for SPMS. It also describes a system by which, owed to the peculiar
432 expansion technique adopted for cGMP expansion (vescovi et al, 1997), the very same hNSCs from a
433 single donor used here, can be used in a broad number of future clinical trials, thereby obviating to
434 the current outstanding issues of inter-trial variability of cell drug products.

435 It is worth noting that, unlike other clinical trials, the cells used in this study are hNSCs that
436 grow as stable, reproducible unmodified cell lines (**Table 8**)

437

438

439 Table 8: Comparison between primary culture (2014) and final product release test (2018 –
440 2020). Data for final product are expressed as mean value of the release tests conducted on
441 all the batches used for the clinical trial. See Profico et al 2022 for complete quality control
442 strategy. IP: intermediate product, FP: final product, CE: Clonal Efficiency; N: Neurons; O:
443 Oligodendrocytes; A: Astrocytes; GC: Growth Curve, expressed as the slope of the growth
444 curve..
445

	IP	FP
CE	1,70%	1,45%
N	27,90%	31,50%
A	36,10%	50,50%
O	17,70%	18,70%
GC	0,076	0,057

446 This is crucial in view of the emerging concept that one key issue in cell therapy is the inter-trial
447 standardization of the cell drug, which may be homogeneous within the same clinical protocol but
448 does vary significantly between different trials, due to the scarcity of the donor cells. The approach
449 used here provides the significant advantage that the very same cGMP hNSCs used here - with all
450 the patients receiving the same cell drug - will also be available for a number of future trials both on
451 SPMS and other disorders. To the best of our knowledge, this is the first report of such an approach
452 being possible.
453
454 In conclusion, NSC transplantation via ICV injection appears to be a safe procedure with neither
455 major nor short-term deleterious effects. The study participants experienced a substantial clinical
456 stability during 12 months of follow-up. The considerable absence of risks for the patients indicates a
457 short-term neutral balance between benefits and risks and a therapeutic possibility on the horizon
458 for SPMS patients. Further studies are needed to confirm and extend the findings herein and
459 evaluate the actual therapeutic potential of advanced cell therapeutics for a condition where the
460 lack of effective disease modifying therapies is a major unmet clinical need.
461

462

463 **DECLARATION OF INTERESTS**

464 **All of the authors declare no conflict of interest**

465

466 **AUTHOR CONTRIBUTIONS**

467 All the authors reviewed and approved the final manuscript

ML	Clinical coordinating investigator, Patients recruitment, data analysis, manuscript writing and approval
CS	Clinical investigator, Patients recruitment, data analysis
DCP	Clinical protocol design, regulatory affairs and administrative management of the study. Biological fluids collection and management, biomarkers analysis, manuscript writing.
MG	Clinical protocol design, regulatory affairs and administrative management of the study. Drug product release, data collection and analysis, manuscript writing.
CC, MZ, LA, GP, CP, FA, PDV, DF, GS, ET, AC, SS, FP, GS, RFB	Clinical data collection and analysis
CG, EP, EZ	Clinical protocol drafting, clinical data collection and analysis
SP, LP	Data analysis, manuscript writing
GM, VG, IB, CR,	Drug product production and release, data collection and evaluation
DF	Non clinical testing, manuscript drafting and revision
ALV	Study coordinator, clinical protocol concept and writing, regulatory affair, provided funding and administrative support, manuscript writing and final approval
MC, AF	Study design, data collection, statistical analysis, manuscript writing
MC	Study management, administrative and regulatory support
JK, GD, LA	Biomarker analysis, data collection and evaluation

468

469

470 **DATA SHARING STATEMENT**

471 All relevant data are included in this manuscript. The data that support the findings of this study are

472 available from the corresponding authors upon reasonable request.

473

474 **ACKNOWLEDGEMENTS**

Writing assistance in the preparation of this article was provided by Maria Carolina Rojido (Medical Writing Consultant). Proofreading and submission assistance was provided by Laura C Collada Ali (Medical Writing Consultant).

FUNDING

Support for writing, proofreading and submission assistance was funded by IRCCS Casa Sollievo della Sofferenza Research Hospital, Italy.

REFERENCES

1. Browne P., Chandraratna D., Angood C., et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022-4.
2. Comi G. Disease-modifying treatments for progressive multiple sclerosis. Mult Scler. 2013;19(11):1428-36.
3. Giovannetti A.M., Pietrolongo E., Borreani C., et al. Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy. PLOS ONE. 2020;15(2):e0228587.
4. Alessandrini M., Preynat-Seauve O., De Bruin K., Pepper M.S. Stem cell therapy for neurological disorders. S Afr Med J. 2019;109(8b):70-7.
5. Lindvall O., Kokaia Z. Stem cells in human neurodegenerative disorders--time for clinical translation? J Clin Invest. 2010;120(1):29-40.
6. Vescovi A.L., Parati E.A., Gritti A., et al. Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Exp Neurol. 1999;156(1):71-83.
7. Ferrari D., Zalfa C., Nodari L.R., et al. Differential pathotropism of non-immortalized and immortalized human neural stem cell lines in a focal demyelination model. Cell Mol Life Sci. 2012;69(7):1193-210.
8. Rota Nodari L., Ferrari D., Giani F., et al. Long-term survival of human neural stem cells in the ischemic rat brain upon transient immunosuppression. PLoS One. 2010;5(11):e14035.
9. Pluchino S., Quattrini A., Brambilla E., et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. 2003;422(6933):688-94.
10. Pluchino S., Gritti A., Blezer E., et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol. 2009;66(3):343-54.
11. Cossetti C., Alfaro-Cervello C., Donegà M., Tyzack G., Pluchino S. New perspectives of tissue remodelling with neural stem and progenitor cell-based therapies. Cell Tissue Res. 2012;349(1):321-9.
12. Giusto E., Donegà M., Cossetti C., Pluchino S. Neuro-immune interactions of neural stem cell transplants: from animal disease models to human trials. Exp Neurol. 2014;260:19-32.
13. Pluchino S., Cossetti C. How stem cells speak with host immune cells in inflammatory brain diseases. Glia. 2013;61(9):1379-401.
14. Peruzzotti-Jametti L., Bernstock J.D., Vicario N., et al. Macrophage-Derived Extracellular Succinate Licenses Neural Stem Cells to Suppress Chronic Neuroinflammation. Cell Stem Cell. 2018;22(3):355-68.e13.
15. Zhang C., Cao J., Li X., et al. Treatment of multiple sclerosis by transplantation of neural stem cells derived from induced pluripotent stem cells. Sci China Life Sci. 2016;59(9):950-7.
16. Takahashi Y., Tsuji O., Kumagai G., et al. Comparative study of methods for administering neural stem/progenitor cells to treat spinal cord injury in mice. Cell Transplant. 2011;20(5):727-39.
17. Ben-Hur T., Fainstein N., Nishri Y. Cell-based reparative therapies for multiple sclerosis. Curr Neurol Neurosci Rep. 2013;13(11):397.

519 18. Peruzzotti-Jametti L., Pluchino S. Therapy with mesenchymal stem cell transplantation in multiple
520 sclerosis ready for prime time: Commentary. Mult Scler. 2022;28(9):1328-9.
521 19. Jin K., Sun Y., Xie L., et al. Comparison of ischemia-directed migration of neural precursor cells after
522 intrastriatal, intraventricular, or intravenous transplantation in the rat. Neurobiol Dis. 2005;18(2):366-74.
523 20. Morgenstern P.F., Connors S., Reiner A.S., Greenfield J.P. Image Guidance for Placement of Ommaya
524 Reservoirs: Comparison of Fluoroscopy and Frameless Stereotactic Navigation in 145 Patients. World
525 Neurosurg. 2016;93:154-8.
526 21. Van Damme P., Robberecht W. Developments in treatments for amyotrophic lateral sclerosis via
527 intracerebroventricular or intrathecal delivery. Expert Opin Investig Drugs. 2014;23(7):955-63.
528 22. Xu X., Chen W., Zhu W., et al. Adeno-associated virus (AAV)-based gene therapy for glioblastoma.
529 Cancer Cell Int. 2021;21(1):76.
530 23. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale
531 (EDSS). Neurology. 1983;33(11):1444-52.
532 24. Fisher D., Beutler L.E., Williams O.B. Making assessment relevant to treatment planning: the STS
533 Clinician Rating Form. Systemic Treatment Selection. J Clin Psychol. 1999;55(7):825-42.
534 25. Burman J., Raininko R., Blennow K., Zetterberg H., Axelsson M., Malmeström C. YKL-40 is a CSF
535 biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol.
536 2016;292:52-7.
537 26. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis:
538 guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-7.
539 27. Mazzini L., Gelati M., Profico D.C., et al. Human neural stem cell transplantation in ALS: initial results
540 from a phase I trial. J Transl Med. 2015;13:17.

541 Solari, A., G. Filippini, L. Mendozzi, A. Ghezzi, S. Cifani, E. Barbieri, S. Baldini, A. Salmaggi, L. L. Mantia,M.
542 Farinotti, D. Caputo and P. Mosconi (1999). "Validation of Italian multiple sclerosis quality of life 54
543 questionnaire." J Neurol Neurosurg Psychiatry 67(2): 158-162.

544 Profico, D.C.; Gelati, M.; Ferrari, D.; Sgaravizzi, G.; Ricciolini, C.; Projetti Pensi, M.; Muzi, G.; Cajola, L.; Copetti,
545 M.; Ciusani, E.; et al. Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization.
546 Int. J. Mol. Sci. 2022, 23, 13425. https:// doi.org/10.3390/ijms232113425

547 Mazzini L, Gelati M, Profico DC, Sorarù G, Ferrari D, Copetti M, Muzi G, Ricciolini C, Carletti S, Giorgi C, Spera C,
548 Frondizi D, Masiero S, Stecco A, Cisari C, Bersano E, De Marchi F, Sarnelli MF, Querin G, Cantello R, Petruzzelli
549 F, Maglione A, Zalfa C, Binda E, Visioli A, Trombetta D, Torres B, Bernardini L, Gaiani A, Massara M, Paolucci S,
550 Boulis NM, Vescovi AL; ALS-NSCs Trial Study Group. Results from Phase I Clinical Trial with Intraspinal Injection
551 of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long-Term Outcome. Stem Cells Transl Med. 2019
552 Sep;8(9):887-897. doi: 10.1002/sctm.18-0154. Epub 2019 May 18. PMID: 31104357; PMCID: PMC6708070.